Abstract
Background: Prognosis for pancreatic cancer remains very poor, and has scarcely improved over the last two decades, with a 5-year overall survival of less than 10%. The only curative option is surgery, which is recommended when full resection of the tumor is possible. In cases of borderline resectable cancer, conventional cytotoxic chemotherapy is used to try to shrink the tumor in order to increase the chance of removing the whole tumor. To improve outcome, hyperthermia (HT) treatment has been suggested as a sensitizer to standard of care therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
